U.S. markets open in 58 minutes

Instil Bio, Inc. (TIL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.64+0.62 (+3.44%)
At close: 4:00PM EDT

Instil Bio, Inc.

3963 Maple Avenue
Suite 350
Dallas, TX 75219
United States
240 676 3715

Full Time Employees242

Key Executives

NameTitlePayExercisedYear Born
Mr. Bronson CrouchChairman & CEO2.37MN/A1973
Dr. Sandeep Laumas M.D.CFO & Chief Bus. Officer639.18kN/A1969
Dr. Zachary Roberts M.D., Ph.D.Chief Medical Officer810.69kN/A1978
Dr. Vijay Chiruvolu M.B.A., Ph.D.Chief Technical OfficerN/AN/A1962
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.

Corporate Governance

Instil Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.